Twin Capital Management Inc. Has $3.15 Million Holdings in Gilead Sciences, Inc. $GILD

Twin Capital Management Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 15.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,337 shares of the biopharmaceutical company’s stock after selling 4,987 shares during the quarter. Twin Capital Management Inc.’s holdings in Gilead Sciences were worth $3,145,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Axim Planning & Wealth bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $293,000. Fortitude Advisory Group L.L.C. acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $237,000. Capital Investment Advisory Services LLC grew its holdings in Gilead Sciences by 2.8% during the 3rd quarter. Capital Investment Advisory Services LLC now owns 6,869 shares of the biopharmaceutical company’s stock worth $763,000 after acquiring an additional 188 shares during the last quarter. Modus Advisors LLC increased its position in Gilead Sciences by 4.3% in the 3rd quarter. Modus Advisors LLC now owns 11,655 shares of the biopharmaceutical company’s stock valued at $1,294,000 after acquiring an additional 478 shares during the period. Finally, Bond & Devick Financial Network Inc. bought a new position in Gilead Sciences during the 3rd quarter worth $242,000. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 373,037 shares of company stock valued at $50,731,512 over the last quarter. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on GILD shares. Wells Fargo & Company raised their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Leerink Partners upped their target price on Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a research report on Friday, January 30th. Morgan Stanley cut their target price on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Finally, UBS Group upped their price target on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $152.50 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm’s 50 day simple moving average is $127.38 and its 200 day simple moving average is $120.91. The firm has a market capitalization of $189.20 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 0.79 and a beta of 0.36. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $153.13.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.